Humoral immunity in elderly persons vaccinated against influenza shortly before cancellation of COVID-19 pandemic
https://doi.org/10.15789/1563-0625-HII-3065
Abstract
Influenza-related morbidity and mortality are disproportionately high among older population. Over 2004-2017, the highest proportion of influenza A(H3N2) virus in the WHO European Region was observed in the age group of ≥ 65 years, i.e., 10%. The efficiency of influenza vaccination is shown to be reduced among individuals over 65-70 years of age, due to age-related immune dysfunction (immunosenescence). It may be associated with an imbalance in effector memory T cells and regulatory responses. In this age group, high-dose or adjuvanted influenza vaccines are potentially more effective in terms of hospitalization days and economy than with non-adjuvanted influenza vaccines used at standard doses. The aim of our study was to investigate the ability to form a protective titer of antibodies to influenza virus among elderly persons after vaccination by the end of the COVID-19 pandemic. A total of 31 participants over 60 years of age took part in the study, who were immunized with an influenza quadrivalent inactivated subunit adjuvant vaccine by intramuscular injections. Antibodies to influenza virus strains were determined by performing a hemagglutination inhibition (HI) test one month after the vaccination. For individuals over 60 years old, one month after vaccination, a statistically significant increase in the seroprotection level (p < 0.05) was observed in relation to three strains: A/Victoria/2570/2019(H1N1) pdm09 (up to 74.2%), A/H3N2/Darwin/9/2021 (93.2%), and B/Austria/1359417/2021 (up to 74.2%). The seroprotection level to the B/Phuket/3073/13 strain was 35.5%. The geometric means of antibody titer (GMT) in older individuals before vaccination was 15.1 (log2 3.91±0.59) for the H1N1 strain versus 73.7 (log2 6.20±0.93) after vaccination; for the H3N2 strain, 52.7 (log2 5.72±0.97) and 147.4 (log2 7.20±1.22), respectively; for the B/Yamagata strain, 8.6 (log2 3.11±0.54) versus 24.1 (log2 4.59±0.79). The GMT level for the B/Victoria strain, was 10.1 (log2 3.33±0.38) versus 63.0 (log2 5.98±0.69) after vaccination. The seroconversion rate (SCR) significantly exceeded the required level of 2.00 for all strains tested (p < 0.05). For both H3N2 and B/Yamagata strains, the GMT was 2.8; for H1N1 and B/Victoria strains, 4.89 and 6.26, respectively. The seroconversion rate for H3N2 and B/Yamagata strains was 41.9%; for the H1N1 strain, 61.3%, for the B/Victoria strain it was 77.4%. The immunogenicity of each component of the influenza vaccine following a single intramuscular immunization of volunteers over 60 years old met at least one criterion of the requirements for inactivated influenza vaccines.
About the Authors
S. V. IushkovaRussian Federation
Iushkova S.V., Postgraduate Student, Department of Epidemiology and Modern Technologies of Vaccination, Institute of Professional Education
Moscow
M. P. Kostinov
Russian Federation
Kostinov M.P., PhD, MD (Medicine), Professor, Corresponding Member, Russian Academy of Sciences, Head, Laboratory of Vaccination and Immunotherapy of Allergic Diseases; Head, Department of Epidemiology and Modern Technologies of Vaccination, Institute of Professional Education
Moscow
L. S. Gladkova
Russian Federation
Gladkova L.S., PhD (Medicine), Deputy Chief Doctor for Sanitary and Epidemiological Issues; Associate Professor, Department of Epidemiology and Social Hygiene, Institute of Medical and Social Technologies
Moscow
A. A. Kameleva
Russian Federation
Kameleva A.A., PhD (Medicine), Allergist-Immunologist, Consultative and Diagnostic Department; Assistant Professor, Department of Clinical Immunology, Allergy, and Adaptation, Faculty of Continuous Medical Education, Medical Institute
Moscow
A. S. Kachnova
Russian Federation
Kachnova A.S., Allergist-Immunologist, Consultative and Diagnostic Department
Moscow
A. M. Kostinova
Russian Federation
Kostinova A.M., PhD (Medicine), Assistant Professor, Department of Epidemiology and Modern Technologies of Vaccination, Institute of Professional Education; AllergistImmunologist, Consultative and Diagnostic Department
Moscow
I. L. Solovyeva
Russian Federation
Solovyeva I.L., PhD, MD (Medicine), Professor, Head, Department of Pediatrics, T. Biktimirov Faculty of Medicine, Institute of Medicine, Ecology and Physical Education
Ulyanovsk
N. P. Andreeva
Russian Federation
Andreeva N.P., PhD (Medicine), Associate Professor, Department of Healthcare Organization and Information Technologies in Medicine; AllergistImmunologist, Republican Family Vaccination Center, Deputy Chief
Cheboksary, Chuvash Republic
Yu. A. Dagil
Russian Federation
Dagil Yu.A., PhD (Biology), Research Associate, Laboratory of Clinical Immunology
Moscow
N. Yu. Nastaeva
Russian Federation
Nastaeva N.Yu., Epidemiologist
Novorossiysk
N. O. Kryukova
Russian Federation
Kryukova N.O., Assistant Professor, Department of Hospital Therapy, Pediatrics Faculty
Moscow
K. A. Saifutdinov
Russian Federation
Saifutdinov K.A., 5th year Student, Faculty of Dentistry
Kazan, Republic of Tatarstan
A. V. Linok
Russian Federation
Linok A.V., PhD (Medicine), Associate Professor, Department of Epidemiology and Modern Technologies of Vaccination, Institute of Professional Education; Research Associate, Laboratory for Epidemiological Analysis and Monitoring of Infectious Diseases
Moscow
I. A. Khrapunova
Russian Federation
Khrapunova I.A., PhD, MD (Medicine), Professor, Department of Epidemiology and Modern Technologies of Vaccination, Institute of Professional Education
Moscow
S. R. Raicic
Russian Federation
Raicic S.R., PhD (Medicine), Assistant Professor, Department of Epidemiology and Modern Technologies of Vaccination, Institute of Professional Education
Moscow
M. N. Loktionova
Russian Federation
Loktionova M.N., PhD (Medicine), Associate Professor, Department of Epidemiology and Modern Technologies of Vaccination, Institute of Professional Education; Leading Research Associate, Laboratory for Epidemiology of Natural Foci Infections; Leading Research Associate, Laboratory of Vaccination and Immunotherapy of Allergic Diseases
Moscow
V. B. Polishchuk
Russian Federation
Polishchuk V.B., PhD (Medicine), Senior Research Associate, Laboratory of Vaccine Prophylaxis and Immunotherapy of Allergic Diseases
Moscow
M. Y. Albahansa
Russian Federation
Albahansa M.Y., Postgraduate Student, Department of Epidemiology and Modern Technologies of Vaccination, Institute of Professional Education
Moscow
References
1. Kostinov M.P. Adult vaccination: from strategy to tactics. Manual for medical professionals. Moscow: Gruppa MDV, 2020. 248 p.
2. Popov S.F., Ioannidi E.A., Alexandrov O.V. Clinical and epidemiological features of the modern course of influenza among elderly patients. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta = Journal of Volgograd State Medical University, 2021, Vol. 77, no. 1, pp. 150-153. (In Russ.)
3. Abreu R.B., Kirchenbaum G.A., Sautto G.A., Clutter E.F., Ross T.M. Impaired memory B-cell recall responses in the elderly following recurrent influenza vaccination. PLoS One, 2021, Vol. 16, no. 8, e0254421. doi: 10.1371/journal.pone.0254421.
4. Alvarez F.P., Chevalier P., Borms M., Bricout H., Marques C., Soininen A., Sainio T., Petit C., de Courville C. Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal. J. Med. Econ., 2023, Vol. 26, no. 1, pp. 710-719.
5. Basu I., Agarwal M., Shah V., Shukla V., Naik S., Supe P.D., Srivastava M.K., Giriraja K.V., Pinjar P., Mishra P.K., Joshi S., Vijayakumar R., van de Witte S. Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India – A phase III, active-controlled, randomized clinical study. Hum. Vaccin. Immunother., 2022, Vol. 18, no. 1, pp. 1-10.
6. Belazi S., Olsen S.J., Brown C., Green H.K., Mook P., Nguyen-Van-Tam J., Penttinen P., Lansbury L. Spotlight influenza: Laboratory-confirmed seasonal influenza in people with acute respiratory illness: a literature review and meta-analysis, WHO European Region, 2004 to 2017. Euro Surveill., 2021, Vol. 26, no. 39, 2000343. doi: 10.2807/1560-7917.ES.2021.26.39.2000343.
7. Centers for Disease Control and Prevention (CDC). Weekly U.S. Influenza Surveillance Report (FluView). Available at: https://www.cdc.gov/flu/weekly/weeklyarchives2023-2024/week11.htm.
8. Domnich A., de Waure C. Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: a systematic review and meta-analysis. Int. J. Infect. Dis., 2022, Vol. 122, pp. 855-863.
9. Doyon-Plourde P., Przepiorkowski J., Young K., Zhao L., Sinilaite A. Intraseasonal waning immunity of seasonal influenza vaccine – A systematic review and meta-analysis. Vaccine, 2023, Vol. 41, no. 31, pp. 4462-4471.
10. Gorse G.J., Grimes S., Buck H., Mulla H., White P., Hill H., May J., Frey S.E., Blackburn P. MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly. Vaccine, 2022, Vol. 40, no. 10, pp. 1472-1482.
11. Izikson R., Brune D., Bolduc J.S., Bourron P., Fournier M., Moore T.M., Pandey A., Perez L., Sater N., Shrestha A., Wague S., Samson S.I. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study. Lancet Respir. Med., 2022, Vol. 10, no. 4, pp. 392-402.
12. Lee J.K.H., Lam G.K.L., Shin T., Samson S.I., Greenberg D.P., Chit A. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and metaanalysis. Vaccine, 2021, Vol. 39, Suppl. 1, pp. A24-A35.
13. Ortiz de Lejarazu R., Martinón Torres F., Gil de Miguel A., Díez Domingo J., Redondo Marguello E. Highdose trivalent influenza vaccine: safety and immunogenicity. Rev. Esp. Quimioter., 2021, Vol. 34, no. 1, pp. 1-11. (In Spanish)
14. Paget J., Staadegaard L., Wang X., Li Y., van Pomeren T., van Summeren J., Dückers M., Chaves S.S., Johnson E.K., Mahé C., Nair H., Viboud C., Spreeuwenberg P. Global and national influenza-associated hospitalisation rates: Estimates for 40 countries and administrative regions. J. Glob. Health, 2023, Vol. 27, no. 13, 04003. doi: 10.7189/jogh.13.04003.
15. Pott H., Andrew M.K., Shaffelburg Z., Nichols M.K., Ye L., ElSherif M., Hatchette T.F., LeBlanc J., Ambrose A., Boivin G., Bowie W., Johnstone J., Katz K., Lagacé-Wiens P., Loeb M., McCarthy A., McGeer A., Poirier A., Powis J., Richardson D., Semret M., Smith S., Smyth D., Stiver G., Trottier S., Valiquette L., Webster D., McNeil S.A. Serious Outcomes Surveillance SOS Network of the Canadian Immunization Research Network CIRN; Toronto Invasive Bacterial Diseases Network TIBDN. Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN). Vaccine, 2023, Vol. 41, no. 42, pp. 6359-6365.
16. Taniguchi K., Ikeda S., Hagiwara Y., Tsuzuki D., Klai M., Sakai Y., Crawford B., Nealon J. Epidemiology and burden of illness of seasonal influenza among the elderly in Japan: A systematic literature review and vaccine effectiveness meta-analysis. Influenza Other Respir. Viruses, 2021, Vol. 15, no. 2, pp. 293-314.
17. Xiao T., Wei M., Guo X., Zhang Y., Wang Z., Xia X., Qi X., Wang L., Li X., Leng S.X. Immunogenicity and safety of quadrivalent influenza vaccine among young and older adults in Tianjin, China: implication of immunosenescence as a risk factor. Immun. Ageing, 2023, Vol. 20, no. 1, 37. doi: 10.1186/s12979-023-00364-6.
Supplementary files
Review
For citations:
Iushkova S.V., Kostinov M.P., Gladkova L.S., Kameleva A.A., Kachnova A.S., Kostinova A.M., Solovyeva I.L., Andreeva N.P., Dagil Yu.A., Nastaeva N.Yu., Kryukova N.O., Saifutdinov K.A., Linok A.V., Khrapunova I.A., Raicic S.R., Loktionova M.N., Polishchuk V.B., Albahansa M.Y. Humoral immunity in elderly persons vaccinated against influenza shortly before cancellation of COVID-19 pandemic. Medical Immunology (Russia). 2025;27(2):395-406. (In Russ.) https://doi.org/10.15789/1563-0625-HII-3065